Pfizer Inc. $PFE Shares Sold by BCS Wealth Management

BCS Wealth Management cut its holdings in Pfizer Inc. (NYSE:PFE) by 50.0% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 26,670 shares of the biopharmaceutical company’s stock after selling 26,670 shares during the period. BCS Wealth Management’s holdings in Pfizer were worth $749,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Horizon Financial Services LLC grew its position in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. acquired a new position in shares of Pfizer during the fourth quarter worth approximately $26,000. YANKCOM Partnership bought a new position in Pfizer in the 4th quarter worth approximately $28,000. HFM Investment Advisors LLC increased its position in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the period. Finally, Abound Financial LLC acquired a new stake in Pfizer in the 4th quarter valued at approximately $31,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Morgan Stanley boosted their price target on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. Bank of America cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Citigroup upped their price objective on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 29th. CICC Research began coverage on shares of Pfizer in a research report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price for the company. Finally, Guggenheim raised their target price on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $28.82.

Pfizer Stock Down 1.3%

PFE opened at $24.75 on Wednesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The company has a market capitalization of $141.06 billion, a PE ratio of 18.89 and a beta of 0.34. The stock’s fifty day moving average is $26.13 and its 200-day moving average is $26.33. Pfizer Inc. has a one year low of $23.11 and a one year high of $28.75.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the business posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 12th. Stockholders of record on Friday, May 8th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer’s payout ratio is currently 131.30%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer is getting credit for longer-term growth optionality in obesity and broader healthcare innovation, with some commentary highlighting its pipeline as an underappreciated driver and its use of AI to improve operations. Pfizer Isn’t Expecting to Make Any Big Acquisition in the Next Couple of Years, but It’s Planning to Do This Instead
• Positive Sentiment: Several articles point to Pfizer’s dividend yield and its obesity pipeline as reasons some investors remain interested in the stock while waiting for new products to ramp. Forget Novo Nordisk. Pfizer’s Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait
• Neutral Sentiment: Pfizer said it will host a webcast of its August 4 second-quarter 2026 results call, which is a routine investor update rather than a direct catalyst. Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts
• Neutral Sentiment: Nike named Pfizer finance executive David Denton as its next CFO, which reflects positively on Pfizer’s leadership bench but is not a direct operating update for PFE shares. Nike Names Pfizer’s Denton as Next CFO
• Negative Sentiment: Pfizer’s experimental lung cancer drug sigvotatug vedotin failed to meet the main overall-survival goal in a late-stage trial versus chemotherapy, a setback that is weighing on sentiment around the stock today. Pfizer’s experimental drug misses main goal of lung cancer trial
• Negative Sentiment: While the drug showed benefit in some subgroups, the mixed readout underscores ongoing execution risk in Pfizer’s oncology portfolio, especially for assets tied to its Seagen acquisition. Pfizer (PFE) Lung Cancer Drug Misses Survival Goal In Phase 3 Trial

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.